Neoadjuvant chemotherapy   

Questions discussed in this category



How would you approach additional systemic therapy? Would the clinical stage of the cancer affect your management?

Why do the NCCN guidelines suggest using neoadjuvant therapy only for patients with T2 or greater tumors?

Are you using post-neoadjuvant Xeloda based on preliminary data from the CREATE-X trial? Does BRCA mutation influence your decision?

(For instance, TCX4 instead of AC->T for smaller tumors?)Does this affect your decision about treating with neoadjuvant versus adjuvant chemotherap...


Papers discussed in this category


N. Engl. J. Med.,

ESMO Open, 2016-01-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003-03-15

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009-03-10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-08-10

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-01-01

Breast Cancer Res. Treat., 2014-09-01

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015-06-10

Lancet Oncol., 2014-06-01

Annals of surgical oncology, 2018-07

Lancet Oncol., 2018 Nov 06